Search

Your search keyword '"Ratjen F"' showing total 947 results

Search Constraints

Start Over You searched for: Author "Ratjen F" Remove constraint Author: "Ratjen F"
947 results on '"Ratjen F"'

Search Results

2. P063 ELX/TEZ/IVA has beneficial effects on clinical outcomes and quality of life in people with cystic fibrosis in the real-world TRAJECTORY study

4. Building global development strategies for cf therapeutics during a transitional cftr modulator era

5. Prenatal depression and birth mode sequentially mediate maternal education's influence on infant sleep duration

6. 137 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 2 and older with cystic fibrosis and at least one F508del allele: 48-week results of an open-label extension study

8. 709 Randomized, double-blind, placebo-controlled trial of oral prednisone as adjunctive treatment in pulmonary exacerbations in cystic fibrosis (PIPE Study)

12. 133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study

16. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study

17. WS01.01 Cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease

18. P077 Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation

19. EPS5.02 Faecal microbiota changes in patients with cystic fibrosis with 6 months of elexacaftor/tezacaftor/ivacaftor: preliminary findings from the PROMISE study

21. 165 Hyperpolarized xenon gas ventilation magnetic resonance imaging detects lung ventilation improvement in children with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor in a multisite study

22. 213 Composition of fecal microbiota and bile acid abundances with 1 month of elexacaftor/tezacaftor/ivacaftor in pediatric patients with cystic fibrosis: Preliminary findings from PROMISE Pediatrics Study

30. 163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study

34. Patterns of allergic sensitization and atopic dermatitis from 1 to 3 years: Effects on allergic diseases

39. Automated airway-artery analysis on chest CT confirms positive effect of inhaled hypertonic saline in preschool children with cystic fibrosis

46. Diagnostik

48. Atemwegserkrankung

49. Diagnostik der cystischen Fibrose

Catalog

Books, media, physical & digital resources